Cited 0 times in
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안중배 | - |
dc.contributor.author | 김세현 | - |
dc.contributor.author | 신상준 | - |
dc.date.accessioned | 2014-12-19T16:36:53Z | - |
dc.date.available | 2014-12-19T16:36:53Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/89861 | - |
dc.description.abstract | PURPOSE: Capecitabine plus oxaliplatin (XELOX) is an effective second-line regimen for advanced colorectal carcinoma (CRC) patients pretreated with irinotecan. Previous studies have shown supra-additive anti-tumor activity of gemcitabine (GEM) when administered with oxaliplatin. We investigated the dose, toxicity, and efficacy of a second-line XELOXGEM regimen in CRC patients pretreated with irinotecan. METHODS: Patients with metastatic or recurrent CRC who failed after a first-line irinotecan-containing regimen received escalating doses of gemcitabine (600, 800, 1,000 mg/m(2) d1, d8) followed by capecitabine (1,000 mg/m(2) b.i.d d1-14) and oxaliplatin (100 mg/m(2) d1) on a 21-day cycle. RESULTS: A total of 38 patients were treated. At 800 mg/m(2), two of six patients experienced dose-limiting toxicities (diarrhea and thrombocytopenia). Therefore, the clinically recommended dose was defined as 600 mg/m(2) gemcitabine (d1, d8) followed by 1,000 mg/m(2) capecitabine (b.i.d dl-14) and 100 mg/m(2) oxaliplatin (d1). The most common grade 3/4 toxicities were neutropenia (32%), thrombocytopenia (13%), anemia (11%), and peripheral neuropathy (11%). Ten (26.3%) and 23 (60.5%) patients experienced partial response and stable disease, respectively. The median progression-free survival and overall survival were 5.4 months (95% CI 3.8-6.9 months) and 17.7 months (95% CI 8.4-26.9 months), respectively. CONCLUSIONS: The XELOXGEM triplet combination is an active and safe second-line regimen for advanced CRC patients pretreated with irinotecan. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Camptothecin/administration & dosage | - |
dc.subject.MESH | Camptothecin/analogs & derivatives | - |
dc.subject.MESH | Capecitabine | - |
dc.subject.MESH | Colorectal Neoplasms/drug therapy* | - |
dc.subject.MESH | Colorectal Neoplasms/pathology | - |
dc.subject.MESH | Deoxycytidine/administration & dosage | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives* | - |
dc.subject.MESH | Deoxycytidine/therapeutic use | - |
dc.subject.MESH | Diarrhea/chemically induced* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Fluorouracil/analogs & derivatives* | - |
dc.subject.MESH | Fluorouracil/therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Maximum Tolerated Dose | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Organoplatinum Compounds/administration & dosage | - |
dc.subject.MESH | Organoplatinum Compounds/therapeutic use* | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Thrombocytopenia/chemically induced* | - |
dc.title | Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Se Hyun Kim | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Sun Young Kim | - |
dc.contributor.googleauthor | Se Hoon Lee | - |
dc.contributor.googleauthor | Young Suk Park | - |
dc.contributor.googleauthor | Se Hoon Park | - |
dc.contributor.googleauthor | Kyung Hee Lee | - |
dc.contributor.googleauthor | Tae Won Kim | - |
dc.contributor.googleauthor | Yong Sang Hong | - |
dc.contributor.googleauthor | Joong Bae Ahn | - |
dc.identifier.doi | 21607556 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A00607 | - |
dc.contributor.localId | A02105 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 21607556 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-011-1668-y | - |
dc.subject.keyword | Capecitabine | - |
dc.subject.keyword | Colorectal carcinoma | - |
dc.subject.keyword | Gemcitabine | - |
dc.subject.keyword | Oxaliplatin | - |
dc.subject.keyword | Second-line | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.alternativeName | Kim, Se Hyun | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Kim, Se Hyun | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.citation.volume | 69 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 91 | - |
dc.citation.endPage | 97 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.69(1) : 91-97, 2012 | - |
dc.identifier.rimsid | 31949 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.